In lab, RNA target weakens triple-negative breast cancer resistance

When treatment damages triple-negative breast cancer cells, the RNA molecule Smyca becomes more abundant instead of fading into the background. Researchers at National Taiwan University, Academia Sinica and Taipei Medical University report that blocking it made tumors more sensitive to chemotherapy and targeted therapy in laboratory studies.

Smyca is a long noncoding RNA, a molecule that does not provide instructions for making proteins but can fine-tune gene activity. The team found that it works with FOXM1, a cancer-promoting transcription factor, to switch on genes involved in repairing damaged DNA and supplying the building blocks needed for that repair.

That mechanism gives tumor cells a way to recover from treatment-induced damage. The researchers used antisense RNA—short genetic material designed to block a specific RNA—and nanoparticle-assisted delivery to target Smyca in tumors. The strategy greatly inhibited DNA repair and sensitized the tumors to chemotherapy and targeted therapy.

The effect was not limited to the tumor cell's repair machinery. With more DNA damage accumulating, Smyca targeting activated the cGAS–STING pathway, an immune-sensing system that alerts the body to abnormal cells. Tumor immunogenicity increased and more immune cells entered the tumors, helping shift an immune-cold environment toward an immune-hot one.

So what changes in practice? Not yet a new treatment for patients. The result identifies a possible way to reinforce therapies already used for triple-negative breast cancer, including chemotherapy, PARP inhibitors for some patients with BRCA mutations and immunotherapy for stage IV disease. The study's evidence remains preclinical, and the findings still need to be tested in clinical trials before Smyca-directed therapy can be considered for routine care.